Subtype
Breast Carcinoma
CI-CAN-00000594Explore in graph →
873 active trials12 approved drugs113 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000594Explore in graph →
Clinical trials
2,394 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (365)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04138719 | Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer | recruiting | Phase 2 | 520 | Hebei Medical University Fourth HospitalOTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT04159142 | Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer | recruiting | Phase 2 | 414 | Hebei Medical University Fourth HospitalOTHER | 1 | Sep 11, 2025 |
| clinicaltrials |
| NCT05107674 | A Study of NX-1607 in Adults With Advanced Malignancies | recruiting | Phase 1 | 345 | Nurix Therapeutics, Inc.INDUSTRY | 2 | Sep 9, 2025 | clinicaltrials |
| NCT05806385 | Grouping Immune-modulation With Cryoablation (LOGIC) for Breast Cancers(LOGIC) | not yet recruiting | Phase 1 / Phase 2 | 36 | Texas Tech University Health Sciences CenterOTHER | 0 | Sep 9, 2025 | clinicaltrials |
| NCT06682793 | A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression(DENALI-1) | recruiting | Phase 1 / Phase 2 | 240 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT07161791 | Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer | not yet recruiting | Phase 1 / Phase 2 | 12 | Harbin Medical UniversityOTHER | 0 | Sep 9, 2025 | clinicaltrials |
| NCT04379570 | Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy | active not recruiting | Phase 3 | 1,167 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT07040644 | A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC | not yet recruiting | Phase 2 | 150 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT05957068 | Breast Cancer Exercise Intervention Study(BREXINT) | recruiting | N/A | 2,156 | National Cancer Centre, SingaporeOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT07153965 | Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast Cancer | not yet recruiting | Phase 2 | 47 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT07139470 | Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer | not yet recruiting | Phase 1 / Phase 2 | 59 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT03165487 | Comparison of the Breast Tumor Microenvironment | active not recruiting | — | 14 | Columbia UniversityOTHER | 1 | Aug 22, 2025 | clinicaltrials |
| NCT03216421 | Intraoperative Radiation Therapy (IORT) in DCIS | active not recruiting | N/A | 265 | Columbia UniversityOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT03170960 | Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 914 | ExelixisINDUSTRY | 9 | Aug 17, 2025 | clinicaltrials |
| NCT06036121 | A Study of ADRX-0706 in Select Advanced Solid Tumors | active not recruiting | Phase 1 | 144 | Adcentrx TherapeuticsINDUSTRY | 2 | Aug 17, 2025 | clinicaltrials |
| NCT06371274 | A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC. | recruiting | N/A | 29 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT07116824 | HB1801 Combined Treatment of HER2-positive Breast Cancer | not yet recruiting | Phase 2 | 80 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Aug 12, 2025 | clinicaltrials |
| NCT03740893 | PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer(PHOENIX) | recruiting | Phase 2 | 119 | Institute of Cancer Research, United KingdomOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT05057013 | A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours | active not recruiting | Phase 1 / Phase 2 | 81 | Cancer Research UKOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT06700070 | A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors | recruiting | Early Phase 1 | 12 | Pure Biologics S.A.INDUSTRY | 1 | Aug 11, 2025 | clinicaltrials |
| NCT07108309 | BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer(AREAL) | recruiting | Phase 2 | 124 | BiocadINDUSTRY | 2 | Aug 7, 2025 | clinicaltrials |
| NCT06973525 | This Study Aims to Optimize Neoadjuvant Therapy for HER2-positive Breast Cancer by Implementing a Dynamic Monitoring-guided Treatment Strategy.(HER2-DM-NACT) | not yet recruiting | Phase 2 | 30 | Hebei Medical University Fourth HospitalOTHER | 0 | Aug 5, 2025 | clinicaltrials |
| NCT07104266 | Triple Negative Breast Cancer and Celecoxib. Pilot Study | recruiting | Phase 2 | 30 | Université de SherbrookeOTHER | 1 | Aug 5, 2025 | clinicaltrials |
| NCT06358625 | Identification of Risk Factors for Brain Recurrence in Patients With HER2-positive Localised Breast Cancer(CRANIUM) | recruiting | — | 120 | Center Eugene MarquisOTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT07007780 | Sacituzumab Tirumotecan in Neoadjuvant Treatment of Early-Stage TNBC | not yet recruiting | Phase 2 | 35 | Xijing HospitalOTHER | 0 | Jul 29, 2025 | clinicaltrials |
| NCT05035745 | Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START) | recruiting | Phase 1 / Phase 2 | 63 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT05491083 | Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer(ComPACT) | recruiting | Phase 1 / Phase 2 | 51 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT07073755 | Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd | recruiting | — | 200 | Hunan Cancer HospitalOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT02436993 | Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab | active not recruiting | Phase 2 | 120 | University of California, IrvineOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT04083963 | Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer | active not recruiting | Phase 2 | 13 | University of Illinois at ChicagoOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT05722795 | Use of Imatinib to Convert Triple Negative Breast Cancer Into ER-positive Breast Cancer (I-CONIC)(I-CONIC) | recruiting | N/A | 40 | Vastra Gotaland RegionOTHER_GOV | 1 | Jul 9, 2025 | clinicaltrials |
| NCT06792721 | MEASUREMENT OF CIRCULATING MUTATION BURDEN(cRISK) | recruiting | — | 30 | Centre Francois BaclesseOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT07047495 | Personalization of External Beam Radiation Therapy in Localised Tumours(MINIONS) | recruiting | — | 35 | European Institute of OncologyOTHER | 1 | Jul 2, 2025 | clinicaltrials |
| NCT07046195 | Optimal Combination of Adjuvant Radiotherapy and Immunotherapy for Breast Cancer | active not recruiting | — | 250 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jul 1, 2025 | clinicaltrials |
| NCT06769425 | HS-10502 Combination Treatment in Patients With Advanced Solid Tumors(HS-10502) | recruiting | Phase 1 | 157 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 24, 2025 | clinicaltrials |
| NCT07030569 | RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study(RADIOSPHER2) | recruiting | — | 500 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Jun 22, 2025 | clinicaltrials |
| NCT07029646 | Comparative Research on the Accuracy of Margin Interpretation in Breast-Conserving Surgery for Breast Cancer: Cell Microscopic Imaging and Standard Frozen Pathology | not yet recruiting | N/A | 167 | Peking University Cancer Hospital & InstituteOTHER | 0 | Jun 19, 2025 | clinicaltrials |
| NCT06150898 | Ketorolac and Pregabalin Effects on breaSt Cancer (KePreSt)(KePreSt) | recruiting | Phase 2 | 112 | Jules Bordet InstituteOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT07019272 | Neratinib in Extended Adjuvant Treatment for HER2+ Early Breast Cancer With pCR But High-Risk Features: A Hebei Multi-Center Real-World Study | not yet recruiting | — | 170 | Hebei Medical University Fourth HospitalOTHER | 0 | Jun 13, 2025 | clinicaltrials |
| NCT07019337 | Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cancer | not yet recruiting | Phase 2 | 100 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Jun 13, 2025 | clinicaltrials |
| NCT07021261 | Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients | not yet recruiting | Phase 3 | 440 | Fudan UniversityOTHER | 0 | Jun 13, 2025 | clinicaltrials |
| NCT07018427 | Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer | active not recruiting | — | 70 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT05346224 | A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer | active not recruiting | Phase 3 | 900 | Shanghai Henlius BiotechINDUSTRY | 4 | Jun 10, 2025 | clinicaltrials |
| NCT07011823 | Immune-checkpoint Blockade After Partial Breast Irradiation by Pembrolizumab in Early TNBC(KEY-MELT) | not yet recruiting | Phase 2 | 20 | Gangnam Severance HospitalOTHER | 0 | Jun 10, 2025 | clinicaltrials |
| NCT07005583 | Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast Cancer | not yet recruiting | Phase 2 | 46 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 5, 2025 | clinicaltrials |
| NCT07003009 | Immun Checkpoint Washout in Patients With Invasive Ductal Breast Cancer | recruiting | N/A | 30 | Istanbul Training and Research HospitalOTHER_GOV | 1 | Jun 4, 2025 | clinicaltrials |
| NCT06049355 | EMBRACE: Exercising Together | recruiting | Phase 2 | 400 | OHSU Knight Cancer InstituteOTHER | 1 | May 29, 2025 | clinicaltrials |
| NCT06991790 | Sacituzumab Govitecan + Toripalimab as First - Line Therapy for Advanced Triple - Negative Breast Cancer and Biomarker Exploration | recruiting | — | 51 | Peking University Cancer Hospital & InstituteOTHER | 1 | May 28, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Sep 11, 2025source: clinicaltrials